Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Lugaresi

Showing results (1-10 of 201) with videos related to

Pageof 21
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|December 17, 2014
Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosisAlessandra Lugaresi
Expert Opinion on Drug Delivery|July 30, 2009
Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?Alessandra Lugaresi
Expert Opinion on Drug Delivery|December 21, 2012
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherenceAlessandra Lugaresi
Expert Opinion on Pharmacotherapy|June 26, 2019
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?Matteo Foschi, Alessandra Lugaresi
Expert Opinion on Pharmacotherapy|August 19, 2020
Ponesimod for the treatment of relapsing multiple sclerosisElisa Baldin, Alessandra Lugaresi
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 7, 2025
Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosisGiannicola Carrozzo, Federica Pinardi, Alessandra Lugaresi
Expert Review of Neurotherapeutics|August 12, 2014
Fostering adherence to injectable disease-modifying therapies in multiple sclerosisAlessandra Lugaresi, Maria Rosa Rottoli, Francesco Patti
Plos One|April 17, 2023
Burden and resources in caregivers of people with multiple sclerosis: A qualitative studyStefano Benini, Erika Pellegrini, Carlo Descovich, et al.
Journal of Clinical Medicine|December 19, 2019
Circadian Activity Rhythm in Early Relapsing-Remitting Multiple SclerosisLorenzo Tonetti, Federico Camilli, Sara Giovagnoli, et al.
Journal of Neuroinflammation|August 12, 2015
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cellsMichela Spadaro, Marzia Caldano, Fabiana Marnetto, et al.
Pageof 21

Showing results (1-10 of 201) with videos related to

Sort By:
Pageof 21
Expert Opinion on Drug Metabolism & Toxicology|December 17, 2014
Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosisAlessandra Lugaresi
Expert Opinion on Drug Delivery|July 30, 2009
Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?Alessandra Lugaresi
Expert Opinion on Drug Delivery|December 21, 2012
RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherenceAlessandra Lugaresi
Expert Opinion on Pharmacotherapy|June 26, 2019
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?Matteo Foschi, Alessandra Lugaresi
Expert Opinion on Pharmacotherapy|August 19, 2020
Ponesimod for the treatment of relapsing multiple sclerosisElisa Baldin, Alessandra Lugaresi
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 7, 2025
Long-term safety evaluation of natalizumab during pregnancy and lactation in patients with multiple sclerosisGiannicola Carrozzo, Federica Pinardi, Alessandra Lugaresi
Expert Review of Neurotherapeutics|August 12, 2014
Fostering adherence to injectable disease-modifying therapies in multiple sclerosisAlessandra Lugaresi, Maria Rosa Rottoli, Francesco Patti
Plos One|April 17, 2023
Burden and resources in caregivers of people with multiple sclerosis: A qualitative studyStefano Benini, Erika Pellegrini, Carlo Descovich, et al.
Journal of Clinical Medicine|December 19, 2019
Circadian Activity Rhythm in Early Relapsing-Remitting Multiple SclerosisLorenzo Tonetti, Federico Camilli, Sara Giovagnoli, et al.
Journal of Neuroinflammation|August 12, 2015
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cellsMichela Spadaro, Marzia Caldano, Fabiana Marnetto, et al.
Pageof 21